Nucleic Acid Therapeutics is the Official Journal of the OTS. It is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal examines nucleic acids as therapeutic agents or modifying nucleic acids for therapeutic purposes including: single and double stranded oligonucleotides, oligonucleotide chemistry, gene modification, aptamers, RNA nanoparticles, and ribozymes.
It welcomes research papers and reviews, but also commentaries on recent oligonucleotide therapeutic developments.OTS members can access the Journal via the member website, and we encourage members to submit their work to the Journal and to recommend the Journal to their library or institution to facilitate collaboration with colleagues. We highly value input from our members and invite you to reach out to us at email@example.com. We also welcome suggestions for special issues focusing on a specific approach, disease field or development stage.
The Journal is led by Co-Editors-in-Chief Bruce A. Sullenger, PhD and Annemieke Aartsma-Rus, PhD, Executive Editor Graham Parker, PhD, Senior Editors David Corey, PhD, Mark Kay, MD, PhD and Brett Monia, PhD, European Editor Jens Kurreck, PhD and Asian Editor Dong-ki Lee, PhD and other leading investigators. View the entire editorial board.
Subscription to Nucleic Acid Therapeutics
Nucleic Acid Therapeutics (formerly Oligonucleotides) is the official journal of the OTS. Your OTS membership includes a discounted subscription to the society’s official journal, Nucleic Acid Therapeutics.
Become a member of the OTS today to start your discounted subscription to Nucleic Acid Therapeutics!